Quantum BioPharma (QNTM)
3.80
-0.13 (3.31%)
Upcoming Events
Latest Headlines
NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis
June 26, 2026 8:30 AM - StreetInsider
Quantum BioPharma MS drug candidate moves toward phase 2 trials
June 25, 2026 8:32 AM - StreetInsider
Quantum BioPharma MS drug candidate nears phase 2 trials
June 25, 2026 8:31 AM - StreetInsider
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
June 25, 2026 8:30 AM - Globe NewsWire
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
June 25, 2026 8:30 AM - StreetInsider
The Quest to Repair What Multiple Sclerosis Takes Away
June 24, 2026 8:30 AM - StreetInsider
Quantum BioPharma's MS drug candidate nears phase 2 trials
June 23, 2026 8:31 AM - StreetInsider
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
June 23, 2026 8:30 AM - StreetInsider
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
June 22, 2026 8:30 AM - StreetInsider
Form 6-K Quantum Biopharma Ltd. For: Jun 02
June 2, 2026 11:51 AM - SEC Filing
Quantum BioPharma hires IR Agency for investor relations services
June 2, 2026 7:40 AM - StreetInsider
Form 6-K Quantum Biopharma Ltd. For: Jun 02
June 2, 2026 7:40 AM - SEC Filing
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
June 2, 2026 7:40 AM - StreetInsider
Form 6-K Quantum Biopharma Ltd. For: May 18
May 18, 2026 6:04 AM - SEC Filing
Quantum BioPharma reaches halfway point in imaging study with MGH
May 18, 2026 5:08 AM - StreetInsider
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
May 18, 2026 3:00 AM - Globe NewsWire
Quantum BioPharma (QNTM) Misses Q1 EPS by 306c
May 7, 2026 7:50 AM - StreetInsider
Quantum BioPharma reports doubled cash position, reduced burn rate
May 7, 2026 7:02 AM - StreetInsider
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
May 7, 2026 7:01 AM - Globe NewsWire
Form 6-K Quantum Biopharma Ltd. For: May 07
May 7, 2026 7:00 AM - SEC Filing
Form 6-K Quantum Biopharma Ltd. For: Mar 31
May 6, 2026 4:15 PM - SEC Filing
Form 6-K Quantum Biopharma Ltd. For: Apr 22
April 22, 2026 9:31 AM - SEC Filing
Unbuzzd Wellness names Richard Buzbuzian CEO for US expansion
April 22, 2026 9:16 AM - StreetInsider
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accel
April 22, 2026 9:16 AM - Globe NewsWire
Quantum BioPharma wins court ruling in $700 million market manipulation case
April 2, 2026 8:31 AM - StreetInsider
Form 6-K Quantum Biopharma Ltd. For: Apr 02
April 2, 2026 8:30 AM - SEC Filing
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securitie
April 2, 2026 8:30 AM - Globe NewsWire
Quantum BioPharma submits IND application to FDA for MS drug trial
April 1, 2026 8:04 AM - StreetInsider
Form 6-K Quantum Biopharma Ltd. For: Apr 01
April 1, 2026 8:02 AM - SEC Filing
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
April 1, 2026 8:02 AM - StreetInsider
Form 6-K Quantum Biopharma Ltd. For: Mar 30
March 30, 2026 7:50 AM - SEC Filing
Quantum BioPharma partners with Allucent for multiple sclerosis trial
March 30, 2026 7:50 AM - StreetInsider
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
March 30, 2026 7:50 AM - StreetInsider
Full Article List
